NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free VIR Stock Alerts $8.10 +0.15 (+1.89%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$7.91▼$8.4050-Day Range$7.95▼$11.9052-Week Range$7.72▼$27.48Volume1.09 million shsAverage Volume1.05 million shsMarket Capitalization$1.09 billionP/E RatioN/ADividend YieldN/APrice Target$34.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vir Biotechnology alerts: Email Address Vir Biotechnology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside324.4% Upside$34.38 Price TargetShort InterestHealthy5.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 4 Articles This WeekInsider TradingSelling Shares$1.53 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.04) to ($3.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.68 out of 5 starsMedical Sector420th out of 909 stocksBiological Products, Except Diagnostic Industry62nd out of 154 stocks 3.3 Analyst's Opinion Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageVir Biotechnology has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.63% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Vir Biotechnology has recently decreased by 8.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIR. Previous Next 1.2 News and Social Media Coverage News SentimentVir Biotechnology has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Vir Biotechnology this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,525,844.00 in company stock.Percentage Held by Insiders18.10% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Vir Biotechnology are expected to grow in the coming year, from ($4.04) to ($3.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Vir Biotechnology Stock (NASDAQ:VIR)Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.Read More VIR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIR Stock News HeadlinesApril 5, 2024 | insidertrades.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Sells 72,995 Shares of StockApril 3, 2024 | insidertrades.comVir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $27,245.55 in StockApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 29, 2024 | insidertrades.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) CFO Sells 6,008 Shares of StockApril 18, 2024 | finance.yahoo.comVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of DirectorsApril 18, 2024 | businesswire.comVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D.April 16, 2024 | morningstar.comVir Biotechnology IncApril 11, 2024 | finance.yahoo.comVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 11, 2024 | businesswire.comVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024April 4, 2024 | finance.yahoo.comVir Biotechnology Inc CEO Backer De Sells 72,995 SharesMarch 21, 2024 | finance.yahoo.comBillionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ PortfolioMarch 19, 2024 | investorplace.comFrom Six Figures to Seven: 3 Biotech Stocks Set to Make MillionairesMarch 16, 2024 | ca.finance.yahoo.comVIR Jul 2024 17.500 callMarch 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR) and IN8bio (INAB)March 15, 2024 | finance.yahoo.comVir Biotechnology, Inc. (VIR)March 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology on Promising HDV and HBV Programs and Strategic Market PositioningMarch 8, 2024 | markets.businessinsider.comMaintaining Buy Rating on ONCY Amidst Promising Clinical Advancements and Partnership PotentialMarch 5, 2024 | finance.yahoo.comVir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of ScheduleFebruary 29, 2024 | finance.yahoo.comVIR Oct 2024 20.000 callFebruary 28, 2024 | seekingalpha.comVir Biotechnology: Making Progress In Hepatitis B And Hepatitis DeltaFebruary 26, 2024 | realmoney.thestreet.comThese 2 Biotech Stocks Are Rising Against the Recent Small-Caps DowntrendFebruary 26, 2024 | investorplace.com3 Highly Rated Biotech Stocks to Buy for 300% GainsFebruary 26, 2024 | markets.businessinsider.comOptimistic Outlook for Vir Biotechnology’s Clinical Programs and Financial Position Reinforces Buy RatingFebruary 25, 2024 | msn.comVir Biotechnology (VIR) Price Target Increased by 9.93% to 33.08February 23, 2024 | markets.businessinsider.comOptimistic Buy Rating on Vir Biotechnology Amidst Advancing HDV and HBV Programs and Upcoming Clinical CatalystsFebruary 23, 2024 | markets.businessinsider.comStrong Buy Rating for Vir Biotechnology on Promising Hepatitis Pipeline and Market Leadership PotentialSee More Headlines Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/22/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIR CUSIPN/A CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees587Year FoundedN/APrice Target and Rating Average Stock Price Target$34.38 High Stock Price Target$110.00 Low Stock Price Target$10.00 Potential Upside/Downside+324.4%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-615,060,000.00 Net Margins-713.69% Pretax Margin-728.93% Return on Equity-34.92% Return on Assets-27.73% Debt Debt-to-Equity RatioN/A Current Ratio9.05 Quick Ratio9.05 Sales & Book Value Annual Sales$39.49 million Price / Sales27.59 Cash FlowN/A Price / Cash FlowN/A Book Value$11.82 per share Price / Book0.69Miscellaneous Outstanding Shares134,500,000Free Float110,156,000Market Cap$1.09 billion OptionableOptionable Beta0.41 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Ann M. Hanly Ph.D. (Age 53)Executive VP & Chief Technology Officer Comp: $842.23kDr. Phillip Pang M.D. (Age 48)Ph.D., Executive VP & Chief Medical Officer Comp: $837.38kDr. Marianne De Backer M.B.A. (Age 54)M.Sc., Ph.D., CEO & Director Dr. Klaus Frueh Ph.D. (Age 64)Co-Founder & Scientific Advisor Comp: $177.66kDr. Lawrence Corey M.D. (Age 76)Co-Founder & Scientific Advisor Dr. Louis J. Picker M.D.Co-Founder & Scientific AdvisorMr. Sung H. Lee (Age 54)Executive VP & CFO Dr. Jennifer Eileen Towne Ph.D.Executive VP & Chief Scientific OfficerMs. Heather Rowe ArmstrongVice President of Investor RelationsMs. Vanina De Verneuil J.D.Executive VP, General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsScholar RockNASDAQ:SRRKTarsus PharmaceuticalsNASDAQ:TARSAdaptimmune TherapeuticsNASDAQ:ADAPKyverna TherapeuticsNASDAQ:KYTXAutolus TherapeuticsNASDAQ:AUTLView All CompetitorsInsiders & InstitutionsHennion & Walsh Asset Management Inc.Bought 4,917 shares on 4/17/2024Ownership: 0.029%Ballentine Partners LLCBought 1,160 shares on 4/11/2024Ownership: 0.010%GAMMA Investing LLCBought 1,934 shares on 4/5/2024Ownership: 0.002%Backer Marianne DeSold 72,995 sharesTotal: $690,532.70 ($9.46/share)Ann M HanlySold 2,711 sharesTotal: $27,245.55 ($10.05/share)View All Insider TransactionsView All Institutional Transactions VIR Stock Analysis - Frequently Asked Questions Should I buy or sell Vir Biotechnology stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VIR shares. View VIR analyst ratings or view top-rated stocks. What is Vir Biotechnology's stock price target for 2024? 7 Wall Street analysts have issued 12 month price targets for Vir Biotechnology's stock. Their VIR share price targets range from $10.00 to $110.00. On average, they expect the company's stock price to reach $34.38 in the next twelve months. This suggests a possible upside of 324.4% from the stock's current price. View analysts price targets for VIR or view top-rated stocks among Wall Street analysts. How have VIR shares performed in 2024? Vir Biotechnology's stock was trading at $10.06 at the beginning of the year. Since then, VIR stock has decreased by 19.5% and is now trading at $8.10. View the best growth stocks for 2024 here. When is Vir Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our VIR earnings forecast. How can I listen to Vir Biotechnology's earnings call? Vir Biotechnology will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) posted its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.14) by $0.28. The company earned $16.80 million during the quarter, compared to analyst estimates of $11.18 million. Vir Biotechnology had a negative net margin of 713.69% and a negative trailing twelve-month return on equity of 34.92%. The firm's revenue for the quarter was down 66.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.76) EPS. What ETFs hold Vir Biotechnology's stock? ETFs with the largest weight of Vir Biotechnology (NASDAQ:VIR) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), iShares Genomics Immunology and Healthcare ETF (IDNA) and ALPS Medical Breakthroughs ETF (SBIO).SPDR S&P 600 Small Cap ETF (SLY). What is George Scangos' approval rating as Vir Biotechnology's CEO? 7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $149 million in an initial public offering on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO. Who are Vir Biotechnology's major shareholders? Vir Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.03%), Ballentine Partners LLC (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Ann M Hanly, Backer Marianne De, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Sung Lee, Vicki L Sato and Vicki L Sato. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIR) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
